80 related articles for article (PubMed ID: 14704688)
1. Cancer trials get set for biomarkers.
Bouchie A
Nat Biotechnol; 2004 Jan; 22(1):6-7. PubMed ID: 14704688
[No Abstract] [Full Text] [Related]
2. GlaxoSmithKline cancer drug threatens Herceptin market.
Waltz E
Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
[No Abstract] [Full Text] [Related]
3. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
Tuma RS
J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
[No Abstract] [Full Text] [Related]
4. Monoclonal antibody successes in the clinic.
Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics--pivotal to the future of the biopharmaceutical industry.
Foot E; Kleyn D; Palmer Foster E
Drug Discov Today; 2010 May; 15(9-10):325-7. PubMed ID: 20298799
[No Abstract] [Full Text] [Related]
6. The HER-2/neu story: from oncogene through prognostic marker to therapeutic strategy determinant and monoclonal therapy.
Mehigan BJ; Kerin MJ
Eur J Surg Oncol; 1999 Apr; 25(2):111-2. PubMed ID: 10218450
[No Abstract] [Full Text] [Related]
7. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
Yan L; Beckman RA
Biotechniques; 2005 Oct; 39(4):565-8. PubMed ID: 16235569
[TBL] [Abstract][Full Text] [Related]
8. PHARMAC responds on Herceptin assumptions and decisions.
Metcalfe S; Evans J
N Z Med J; 2007 Aug; 120(1260):U2692. PubMed ID: 17726504
[No Abstract] [Full Text] [Related]
9. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer.
Pusztai L; Anderson K; Hess KR
Clin Cancer Res; 2007 Oct; 13(20):6080-6. PubMed ID: 17947471
[TBL] [Abstract][Full Text] [Related]
10. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
Altundag K; Baptista MZ
Breast J; 2006; 12(5):497-8. PubMed ID: 16958977
[No Abstract] [Full Text] [Related]
11. Promises of biomarkers in drug development--a reality check.
Marrer E; Dieterle F
Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
[TBL] [Abstract][Full Text] [Related]
12. Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system.
Nat Rev Drug Discov; 2011 Aug; 10(9):648. PubMed ID: 21878969
[No Abstract] [Full Text] [Related]
13. Perspectives and challenges of clinical pharmacogenomics in cancer.
Pusztai L
Pharmacogenomics; 2004 Jul; 5(5):451-4. PubMed ID: 15212580
[No Abstract] [Full Text] [Related]
14. Tumor-associated antigens and biomarkers in cancer and immune therapy.
Malyankar UM
Int Rev Immunol; 2007; 26(3-4):223-47. PubMed ID: 17558745
[TBL] [Abstract][Full Text] [Related]
15. Retrospective validation of genomic biomarkers-- what are the questions, challenges and strategies for developing useful relationships to clinical outcomes-- workshop summary.
Wang SJ; Cohen N; Katz DA; Ruano G; Shaw PM; Spear B
Pharmacogenomics J; 2006; 6(2):82-8. PubMed ID: 16402078
[No Abstract] [Full Text] [Related]
16. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Rowan K
J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
[No Abstract] [Full Text] [Related]
17. [Brief overview on the studies of monoclonal antibody].
Tsukagoshi S
Nihon Rinsho; 2002 Mar; 60(3):435-8. PubMed ID: 11904954
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant trastuzumab for breast cancer: advent of pharmacogenetics raises many issues.
Thornton H
BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293848
[No Abstract] [Full Text] [Related]
19. Human epidermal growth factor receptor 2 testing: where are we?
De P; Smith BR; Leyland-Jones B
J Clin Oncol; 2010 Oct; 28(28):4289-92. PubMed ID: 20697080
[No Abstract] [Full Text] [Related]
20. The cancer biomarker problem.
Sawyers CL
Nature; 2008 Apr; 452(7187):548-52. PubMed ID: 18385728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
